Cargando…

Antimicrobial Activities of Fidaxomicin

Fidaxomicin is bactericidal against Clostridium difficile. The combined results of 8 in vitro studies of 1323 C. difficile isolates showed the minimum inhibitory concentration (MIC) range of fidaxomicin to be ≤0.001–1 μg/mL, with a maximum MIC for inhibition of 90% of organisms (MIC(90)) of 0.5 μg/m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goldstein, Ellie J. C., Babakhani, Farah, Citron, Diane M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2012
Materias:	Supplement Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388021/ https://www.ncbi.nlm.nih.gov/pubmed/22752863 http://dx.doi.org/10.1093/cid/cis339

Ejemplares similares

Fidaxomicin Inhibits Spore Production in Clostridium difficile
por: Babakhani, Farah, et al.
Publicado: (2012)

Relapse Versus Reinfection: Recurrent Clostridium difficile Infection Following Treatment With Fidaxomicin or Vancomycin
por: Figueroa, Iris, et al.
Publicado: (2012)

Reduced Acquisition and Overgrowth of Vancomycin-Resistant Enterococci and Candida Species in Patients Treated With Fidaxomicin Versus Vancomycin for Clostridium difficile Infection
por: Nerandzic, Michelle M., et al.
Publicado: (2012)

Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA Synthesis
por: Artsimovitch, Irina, et al.
Publicado: (2012)

Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
por: Cornely, Oliver A., et al.
Publicado: (2012)

Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections
por: Weiss, Karl, et al.
Publicado: (2012)

Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
por: Crook, Derrick W., et al.
Publicado: (2012)

Fidaxomicin Attains High Fecal Concentrations With Minimal Plasma Concentrations Following Oral Administration in Patients With Clostridium difficile Infection
por: Sears, Pamela, et al.
Publicado: (2012)

Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
por: Louie, Thomas J., et al.
Publicado: (2012)

Whole-Genome Sequencing Demonstrates That Fidaxomicin Is Superior to Vancomycin for Preventing Reinfection and Relapse of Infection With Clostridium difficile
por: Eyre, David W., et al.
Publicado: (2014)

In vitro activity of fidaxomicin and combinations of fidaxomicin with other antibiotics against Clostridium perfringens strains isolated from dogs and cats
por: Álvarez-Pérez, Sergio, et al.
Publicado: (2023)

Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against 162 Strains from 35 Less Frequently Recovered Intestinal Clostridium Species: Implications for Clostridium difficile Recurrence
por: Goldstein, Ellie J. C., et al.
Publicado: (2014)

An Economic Analysis: Is Fidaxomicin Worth the Cost?
por: Shah, Hemal, et al.
Publicado: (2014)

675. The Fidaxomicin Cascade: Analysis of Success Rates and Barriers of Fidaxomicin Discharge Prescriptions for Inpatients Diagnosed with Clostridiodes Difficile
por: Cook, Ellen, et al.
Publicado: (2023)

Comparative In Vitro Activities of SMT19969, a New Antimicrobial Agent, against Clostridium difficile and 350 Gram-Positive and Gram-Negative Aerobic and Anaerobic Intestinal Flora Isolates
por: Goldstein, Ellie J. C., et al.
Publicado: (2013)

Fidaxomicin - the new drug for Clostridium difficile infection
por: Vaishnavi, Chetana
Publicado: (2015)

Antimicrobial Resistance in Typhoidal Salmonella: Around the World in 3 Days
por: Saha, Senjuti, et al.
Publicado: (2020)

Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
por: Oliver, Meredith B, et al.
Publicado: (2022)

START Stewardship Tactics for Antimicrobial Resistance Trends
por: Rodvold, Keith A., et al.
Publicado: (2009)

Comparison of Antimicrobial Stewardship and Infection Prevention and Control Activities and Resources Between Low-/Middle- and High-income Countries
por: Villanueva, Paola, et al.
Publicado: (2022)

Emerging therapies for Clostridium difficile infection – focus on fidaxomicin
por: Chaparro-Rojas, Fredy, et al.
Publicado: (2013)

Novel fidaxomicin antibiotics through site-selective catalysis
por: Dailler, David, et al.
Publicado: (2021)

Fidaxomicin Use and Clinical Outcomes for Clostridium difficile–Associated Diarrhea
por: Eiland, Edward H., et al.
Publicado: (2015)

Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
por: Khoo, Teresa, et al.
Publicado: (2017)

In Vitro Activity of Eravacycline and Comparator Antimicrobials Against 143 Strains of Bacteroides Species.
por: Citron, Diane, et al.
Publicado: (2017)

Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection
por: Zhanel, George G, et al.
Publicado: (2015)

Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin
por: Maaß, Sandra, et al.
Publicado: (2018)

Fidaxomicin to prevent recurrent Clostridioides difficile: what will it cost in the USA and Canada?
por: Patel, Devangi, et al.
Publicado: (2023)

The Impact of Antimicrobial Stewardship in Children in Low- and Middle-income Countries: A Systematic Review
por: Abo, Yara-Natalie, et al.
Publicado: (2022)

Semisynthetic Analogs of the Antibiotic Fidaxomicin—Design, Synthesis, and Biological Evaluation
por: Dorst, Andrea, et al.
Publicado: (2020)

Fidaxomicin as a Salvage Therapy for Fulminant Clostridioides difficile Infection
por: Heleno, Caio T, et al.
Publicado: (2021)

Molecular dissection of RbpA-mediated regulation of fidaxomicin sensitivity in mycobacteria
por: Prusa, Jerome, et al.
Publicado: (2022)

Antimicrobial Resistance in Typhoidal Salmonella: Surveillance for Enteric Fever in Asia Project, 2016–2019
por: Qamar, Farah N, et al.
Publicado: (2020)

Antimicrobial resistance in Neisseria gonorrhoeae and Treponema pallidum: evolution, therapeutic challenges and the need to strengthen global surveillance
por: Lewis, David A, et al.
Publicado: (2011)

Activity of Ceftaroline against Aerobic Gram-Positive and Gram-Negative Pathogens: Effect of Test Method Variability
por: Citron, Diane M., et al.
Publicado: (2011)

Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes
por: Lee, Christine, et al.
Publicado: (2016)

Comparison of the Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Healthy Japanese and Caucasian Subjects
por: Oshima, Hiroyuki, et al.
Publicado: (2015)

COVID-19 therapeutics: stewardship in England and considerations for antimicrobial resistance
por: Bou-Antoun, Sabine, et al.
Publicado: (2023)

A multi-center study of fidaxomicin use for Clostridium difficile infection
por: Shah, Dhara N., et al.
Publicado: (2016)

The Importance of Antimicrobial Resistance Monitoring Worldwide and the Origins of SENTRY Antimicrobial Surveillance Program
por: Fuhrmeister, Andrew S, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2mc736dphitd49c8e6ndc124nh